| Literature DB >> 26957901 |
Karen Dionne1, Rachel L Redfern1, Jason J Nichols1, Kelly K Nichols1.
Abstract
PURPOSE: Inflammatory mediators have been shown to modulate dry eye (DE) disease and may correlate with disease severity, yet the methods used and the associated findings vary significantly in the literature. The goal of this research was to compare two methods, the quantitative microarray and the magnetic bead assay, for detecting cytokine levels in extracted tear samples across three subject groups.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26957901 PMCID: PMC4767412
Source DB: PubMed Journal: Mol Vis ISSN: 1090-0535 Impact factor: 2.367
Schirmer strip wetting length and total protein concentrations.
| Subject | Measure | OD (mm) | OS (mm) | (OD+OS; mm) | Protein (ug/ul) | Correlation (Sum (OD+OS), Protein) |
|---|---|---|---|---|---|---|
| ALL | Average | 20.60±11.75 | 18.33±11.23 | 38.93±21.08 | 83.93±37.01 | r=0.61, p=0.0000001 |
| Range | (1, 35) | (0, 35) | (1, 70) | (29, 208) | ||
| P value | 0.282391 | |||||
| DE | Average | 14.95±12.61 | 11.45±8.45 | 26.4±18.43 | 75.64525±30.97 | r=0.56, p=0.004 |
| Range | (1, 35) | (0, 35) | (1, 70) | (35, 142) | ||
| P value | 0.309808 | |||||
| CL | Average | 25.70±8.26 | 23.90±8.94 | 49.60±15.10 | 98.94±35.67 | r=0.33, p=0.08 |
| Range | (14, 35) | (9, 35) | (24, 70) | (58, 208) | ||
| P value | 0.512334 | |||||
| NOR | Average | 21.15±11.87 | 19.65±12.49 | 40.80±22.87 | 77.19±40.78 | r=0.77, p=0.00004 |
| Range | (2, 35) | (2, 35) | (4, 70) | (29, 159)* | ||
| P value | 0.699171 |
*indicates the lowest value of protein concentration to which all other samples were normalized +Total protein concentrations are before aliquot taken for quantitation
Figure 1Average inflammatory mediator expression levels for each method and group. A: Contact lens (CL) group: For the microarray, eight inflammatory mediators had expression levels greater than the minimum detectable level (MDL) of the assay for the contact lens wearers: ICAM-1, MCP-1, MIG, GM-CSF, Eotaxin-2, IL-1ra, TIMP-1, and TIMP-2. Dry eye (DE) group: Of the inflammatory mediators represented in the microarray, eight had expression levels greater than the MDL: ICAM-1, IL-16, MCP-1, MCSF, MIG, TIMP-1, TIMP-2, and TNF-RI. Non-contact lens (NOR) group: For the non-contact lens wearers, six inflammatory mediators included in the microarray showed expression levels greater than the MDL: MCP-1, MCSF, MIG, TIMP-1, TIMP-2, and TNF-RI. B: CL group: Among the 12 inflammatory cytokines and one chemokine present in the Luminex magnetic bead kit, only four had expression levels greater than the MDL: IL-1β, IL-6, IL-7, and IL-8. Of these, only IL-7 was shown to express in all the subjects in the group. DE group: Of the 13 inflammatory mediators present in the Luminex magnetic bead kit, four had expression levels greater than the MDL of the assay: IL-1β, IL-6, IL-7, and IL-8. Of these four analytes, only IL-8 was present in all the subjects in the group, with IL-1β expression occurring the least, in only two subjects. NOR group: For the Luminex magnetic bead kit, four mediators showed detectable levels of expression: IL-4, IL-6, IL-7, and IL-8. Of these, only IL-7 and IL-8 were present in all the subjects in this group, with IL-4 occurring the least, expressing in only four subjects.
Analytes and the limits of detection (LOD) included in each assay
| IL-1β | 4.49 | 0.06 |
| IL-2 | 23.42 | 0.26 |
| IL-4 | 12.35 | 0.42 |
| IL-5 | 19.99 | 0.04 |
| IL-6 | 11.47 | 0.2 |
| IL-7 | 9.38 | 0.2 |
| IL-8 | 9.47 | 0.05 |
| IL-10 | 15.24 | 0.48 |
| IL-12p70 | 1.98 | 0.34 |
| IL-13 | 5.98 | 0.18 |
| IFNγ | 43.89 | 0.18 |
| GM-CSF | 12.06 | 0.15 |
| TNFα | 25.25 | 0.07 |
| BLC | 9.37 | |
| Eotaxin | 8.58 | |
| Eotaxin-2 | 3.11 | |
| G-CSF | 23.99 | |
| I-309 | 12.65 | |
| ICAM-1 | 95.82 | |
| IL-1α | 14.56 | |
| IL-1ra | 253.45 | |
| IL-6sR | 24.99 | |
| IL-11 | 78.10 | |
| IL-12p40 | 39.48 | |
| IL-15 | 77.23 | |
| IL-16 | 17.93 | |
| IL-17 | 24.83 | |
| MCP-1 | 12.05 | |
| MCSF | 4.23 | |
| MIG | 74.91 | |
| MIP-1a | 4.23 | |
| MIP-1b | 0.50 | |
| MIP-1d | 6.47 | |
| PDGF-BB | 9.16 | |
| RANTES | 6.60 | |
| TIMP-1 | 21.46 | |
| TIMP-2 | 51.22 | |
| TNFβ | 83.58 | |
| TNF RI | 81.68 | |
| TNF RII | 34.51 |
Statistical significance between subject groups as detected by both methods.
| Eotaxin-2 | p=0.034 | CL | p=0.367 | n/a | p=0.002 | CL | |
| G-CSF | p=0.012 | DE | p=0.039 | DE | p=0.641 | n/a | |
| GM-CSF | p<0.001 | CL | p=0.455 | n/a | p<0.001 | CL | |
| I-309 | p=0.114 | n/a | p=0.411 | n/a | p=0.006 | CL | |
| ICAM-1 | p=0.039 | DE | p=0.001 | CL | |||
| IFNg | p=0.037 | DE | p=0.897 | n/a | p=0.003 | NOR | |
| IL-2 | p=0.023 | DE | p=0.535 | n/a | p<0.001 | NOR | |
| IL-6 | p=0.634 | n/a | p<0.001 | NOR | |||
| IL-6sR | p<0.001 | DE | p=0.807 | n/a | p<0.001 | NOR | |
| IL-7 | p=0.111 | n/a | p=0.772 | n/a | p=0.041 | NOR | |
| IL-12p40 | p=0.047 | DE | p=0.931 | n/a | p=0.008 | NOR | |
| IL-13 | p=0.831 | n/a | p=0.109 | n/a | p=0.025 | NOR | |
| MCP-1 | p=0.637 | n/a | p=0.095 | n/a | p=0.045 | CL | |
| MCSF | p<0.001 | DE | p=0.552 | n/a | p<0.001 | NOR | |
| MIP-1a | p<0.001 | DE | p=0.587 | n/a | p=0.001 | NOR | |
| TIMP-1 | p<0.001 | DE | p=0.551 | n/a | p<0.001 | NOR | |
| TIMP-2 | p=0.143 | n/a | p=0.083 | n/a | p=0.001 | NOR | |
| TNFb | p=0.012 | DE | p=0.227 | n/a | p<0.001 | NOR | |
| TNF RI | p<0.001 | DE | p=0.567 | n/a | p<0.001 | NOR | |
| TNF RII | p=0.006 | DE | p=0.472 | n/a | p=0.006 | NOR |
Red, significant Bold, borderline significant Black, not significant n/a, not applicable, there were not two data sets to compare
Comparison of key factors between methods.
| Limit of Detection | Limit of detection is calculated for each slide as a function of background intensity. | |
| Reliability | ||
| Standard Deviation | ||
| Standard Curve | ||
| Binding Affinity | ||
| Sample Prep | ||
| Ease of Use | Scanning can be optimized for more reliable results. |
Normal font indicates the preferable method for the associated factor, bold font indicates no preference
Percentage of subjects in each group with analyte* expression levels above the LOD for both methods.
| Analytes | ||||||
|---|---|---|---|---|---|---|
| Luminex | Microarray | Luminex | Microarray | Luminex | Microarray | |
| IL-1b | 30% | 5% | 15% | 15% | 20% | 5% |
| IL-2 | 0% | 20% | 0% | 35% | 0% | 50% |
| IL-4 | 30% | 30% | 20% | 5% | 15% | 10% |
| IL-5 | 0% | 0% | 0% | 5% | 0% | 0% |
| IL-6 | 55% | 10% | 80% | 25% | 45% | 35% |
| IL-7 | 100% | 0% | 90% | 25% | 100% | 20% |
| IL-8 | 100% | 20% | 100% | 25% | 100% | 25% |
| IL-10 | 0% | 0% | 0% | 0% | 5% | 0% |
| IL-12(p70) | 0% | 5% | 0% | 15% | 0% | 20% |
| IL-13 | 20% | 10% | 15% | 25% | 20% | 35% |
| IFNy | 0% | 0% | 0% | 20% | 0% | 10% |
| GM-CSF | 0% | 40% | 0% | 5% | 0% | 0% |
| TNFα | 0% | 15% | 5% | 0% | 0% | 0% |
*Of analytes present in both methods. The analytes are only those present both methods in both the Luminex High Sensitivity Human Cytokine Magnetic Bead Kit and the Raybiotech Quanitbody® Human Inflammation Array 3.